Literature DB >> 27939673

Perinatal Activation of the Interleukin-33 Pathway Promotes Type 2 Immunity in the Developing Lung.

Ismé M de Kleer1, Mirjam Kool2, Marjolein J W de Bruijn3, Monique Willart2, Justine van Moorleghem2, Martijn J Schuijs2, Maud Plantinga4, Rudi Beyaert5, Emily Hams6, Padraic G Fallon6, Hamida Hammad2, Rudi W Hendriks3, Bart N Lambrecht7.   

Abstract

Allergic disease originates in early life and polymorphisms in interleukin-33 gene (IL33) and IL1RL1, coding for IL-33R and decoy receptor sST2, confer allergy risk. Early life T helper 2 (Th2) cell skewing and allergy susceptibility are often seen as remnants of feto-maternal symbiosis. Here we report that shortly after birth, innate lymphoid type 2 cells (ILC2s), eosinophils, basophils, and mast cells spontaneously accumulated in developing lungs in an IL-33-dependent manner. During the phase of postnatal lung alveolarization, house dust mite exposure further increased IL-33, which boosted cytokine production in ILC2s and activated CD11b+ dendritic cells (DCs). IL-33 suppressed IL-12p35 and induced OX40L in neonatal DCs, thus promoting Th2 cell skewing. Decoy sST2 had a strong preventive effect on asthma in the neonatal period, less so in adulthood. Thus, enhanced neonatal Th2 cell skewing to inhaled allergens results from postnatal hyperactivity of the IL-33 axis during a period of maximal lung remodeling.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-33; IL1RL1; ILC2; allergic asthma; alveolarization; dendritic cells; early life; eosinophils; house dust mite; lung development

Mesh:

Substances:

Year:  2016        PMID: 27939673     DOI: 10.1016/j.immuni.2016.10.031

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  117 in total

1.  Targeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma.

Authors:  Kruti R Patel; Yan Bai; Kenneth G Trieu; Juliana Barrios; Xingbin Ai
Journal:  FASEB J       Date:  2017-06-15       Impact factor: 5.191

Review 2.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

3.  Allergy: Neonatal IL-33 drives allergy.

Authors:  Lydia Shipman
Journal:  Nat Rev Immunol       Date:  2017-01-03       Impact factor: 53.106

Review 4.  Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease.

Authors:  Hiam Abdala-Valencia; Mackenzie E Coden; Sergio E Chiarella; Elizabeth A Jacobsen; Bruce S Bochner; James J Lee; Sergejs Berdnikovs
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

5.  Insulin-like Growth Factor 1 Supports a Pulmonary Niche that Promotes Type 3 Innate Lymphoid Cell Development in Newborn Lungs.

Authors:  Katherine Oherle; Elizabeth Acker; Madeline Bonfield; Timothy Wang; Jerilyn Gray; Ian Lang; James Bridges; Ian Lewkowich; Yan Xu; Shawn Ahlfeld; William Zacharias; Theresa Alenghat; Hitesh Deshmukh
Journal:  Immunity       Date:  2020-02-18       Impact factor: 31.745

Review 6.  Professional and 'Amateur' Antigen-Presenting Cells In Type 2 Immunity.

Authors:  Martijn J Schuijs; Hamida Hammad; Bart N Lambrecht
Journal:  Trends Immunol       Date:  2018-11-27       Impact factor: 16.687

Review 7.  Does tissue imprinting restrict macrophage plasticity?

Authors:  Martin Guilliams; Freya R Svedberg
Journal:  Nat Immunol       Date:  2021-01-18       Impact factor: 25.606

Review 8.  Innate lymphoid cells: major players in inflammatory diseases.

Authors:  Mikaël Ebbo; Adeline Crinier; Frédéric Vély; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2017-08-14       Impact factor: 53.106

Review 9.  Unique aspects of the perinatal immune system.

Authors:  Xiaoming Zhang; Dania Zhivaki; Richard Lo-Man
Journal:  Nat Rev Immunol       Date:  2017-06-19       Impact factor: 53.106

Review 10.  Type 2 immunity in tissue repair and fibrosis.

Authors:  Richard L Gieseck; Mark S Wilson; Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.